Cargando…

Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Borsani, Oscar, Bastard, Paul, Rosain, Jérémie, Gervais, Adrian, Sant’Antonio, Emanuela, Vanni, Daniele, Casetti, Ilaria Carola, Pietra, Daniela, Trotti, Chiara, Catricalà, Silvia, Ferretti, Virginia Valeria, Malcovati, Luca, Arcaini, Luca, Casanova, Jean-Laurent, Borghesi, Alessandro, Rumi, Elisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Letter to Blood
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047990/ https://www.ncbi.nlm.nih.gov/pubmed/35100354 http://dx.doi.org/10.1182/blood.2021014890

Ejemplares similares

Autoantibodies Against Type I IFNs in Patients with Ph-Negative Myeloproliferative Neoplasms
por: Borsani, Oscar, et al.
Publicado: (2021)

Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms
por: Vanni, Daniele, et al.
Publicado: (2022)

Isolated congenital asplenia: An overlooked cause of thrombocytosis
por: Borsani, Oscar, et al.
Publicado: (2022)

Risk of Thrombosis in Myeloproliferative Neoplasms after Sars-Cov-2 Vaccination
por: Borsani, Oscar, et al.
Publicado: (2022)

P984: MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Casetti, I. C., et al.
Publicado: (2022)

SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms
por: Borsani, Oscar, et al.
Publicado: (2023)

The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance
por: Rumi, Elisa, et al.
Publicado: (2020)

COVID-19 in Patients with Hematologic Diseases
por: Casetti, Ilaria Carola, et al.
Publicado: (2022)

Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2021)

Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2022)

Low Lymphocytes and IFN-Neutralizing Autoantibodies as Biomarkers of COVID-19 Mortality
por: Troya, Jesús, et al.
Publicado: (2022)

Impaired thymic AIRE expression underlies autoantibodies against type I IFNs in humans with inborn errors of the alternative NF-κB pathway
por: Voyer, Tom Le, et al.
Publicado: (2023)

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
por: Pietra, D, et al.
Publicado: (2016)

No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients
por: Philippot, Quentin, et al.
Publicado: (2023)

Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms
por: Cavalloni, Chiara, et al.
Publicado: (2017)

Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia
por: Philippot, Quentin, et al.
Publicado: (2023)

Interferon-β Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2
por: Bastard, Paul, et al.
Publicado: (2021)

Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers
por: DeMarshall, Cassandra A., et al.
Publicado: (2016)

Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients
por: Gervais, Adrian, et al.
Publicado: (2023)

Autoantibodies against type I IFNs in patients with critical influenza pneumonia
por: Zhang, Qian, et al.
Publicado: (2022)

Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain
por: Troya, Jesús, et al.
Publicado: (2021)

Human autoantibodies underlying infectious diseases
por: Puel, Anne, et al.
Publicado: (2022)

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
por: Pecquet, Christian, et al.
Publicado: (2023)

Red cell–bound antibodies and transfusion requirements in hospitalized patients with COVID-19
por: Berzuini, Alessandra, et al.
Publicado: (2020)

Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report
por: Cuneo, Antonio, et al.
Publicado: (2020)

Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma
por: Vazquez, Sara E., et al.
Publicado: (2021)

Arginase‐1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver
por: Bonometti, Arturo, et al.
Publicado: (2022)

Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-thalassemia: role of an additional dose
por: Carsetti, Rita, et al.
Publicado: (2022)

Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs
por: Lopez, Jonathan, et al.
Publicado: (2021)

Correction: Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs
por: Lopez, Jonathan, et al.
Publicado: (2021)

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1
por: Bastard, Paul, et al.
Publicado: (2021)

Performance characteristics of a novel blood bag in-line closure device and subsequent product quality assessment
por: Serrano, Katherine, et al.
Publicado: (2010)

Failure of self-disclosure of deferrable risk behaviors associated with transfusion-transmissible infections in blood donors
por: Wong, Horas Tze Hoo, et al.
Publicado: (2015)

Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone
por: Tedder, Richard S., et al.
Publicado: (2018)

Estimation of the number of blood donors during the COVID‐19 incubation period across China and analysis of prevention and control measures for blood transfusion transmission
por: Yuan, Zhaohu, et al.
Publicado: (2020)

Deferral rate variability in blood donor eligibility assessment
por: de Kort, Wim, et al.
Publicado: (2018)

Ensuring HLA‐matched platelet support requires an ethnic diverse donor population
por: Kreuger, Aukje L., et al.
Publicado: (2020)

First results of a ferritin‐based blood donor deferral policy in the Netherlands
por: Vinkenoog, Marieke, et al.
Publicado: (2020)

Determinants of blood donation willingness in the European Union: a cross‐country perspective on perceived transfusion safety, concerns, and incentives
por: Huis in ‘t Veld, Elisabeth M.J., et al.
Publicado: (2019)

Prediction paradigm involving time series applied to total blood issues data from England
por: Nandi, Anita K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ui1240sdpfebp76rmrru8fo1k1